Halozyme Therapeutics
$106.94Change from previous close: −3.13%Absolute change: −$3.46
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $12.14B
- Enterprise value
- $14.09B
- P/E (trailing 12 months)
- 31.4
- Forward P/E
- 10.3
- Price/book
- 84.9
- Price/sales
- 7.30
- EV/EBITDA
- 13.4
- EV/revenue
- 8.47
Profitability and growth
- Gross margin
- 76.3%
- Operating margin
- 59.8%
- Net margin
- 24.9%
- ROE
- 173.7%
- ROA
- 25.5%
- Revenue growth (year over year)
- 47.7%
- Earnings growth (year over year)
- 42.9%
Financial health
- Total cash
- $231M
- Total debt
- $2.18B
- Debt/equity
- 15.2
- Current ratio
- 2.71
- Quick ratio
- 1.99
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $99.56
- Median price target
- $105.00
- High price target
- $115.00
- Low price target
- $70.00
- Analysts with a price target
- 9
- Forward EPS
- $10.39
- EPS estimate, current year
- $8.58
Shares and trading
- Beta
- 0.88
- Average volume
- 2.18M
- Shares outstanding
- 113.5M
- Float
- 112.19M
- Institutional ownership
- 112.0%
- Insider ownership
- 1.1%
- Short interest (% of float)
- 17.5%
- Short ratio (days)
- 9.83